- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02983240
Electrical Inhibition of Human Preterm Contractions
Electrical Inhibition (EI): A Preliminary Study to Prevent the Uterine Contractions of Human Preterm Labor and Preterm Birth
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the effectiveness of a new method of preventing the human preterm uterine contractions of labor during electrical monitoring. The objective is to test a method for the inhibition of human preterm uterine contractions with an electrical pacemaker, electrical inhibition (EI). The study will investigate EI associated changes in preterm uterine contraction frequency as monitored by objective uterine tocodynamometry and adjunct electromyography (EMG) and electrohysterogram (EHG). The endpoint is the statistically significant EI induced decrease in the gold standard tocodynamometric monitored preterm uterine contraction frequency. The adjunct EMG and EHG monitoring provides valuable adjunct data about the electrical activity of the preterm uterine contractions and the effect of EI on this activity.
The investigators hypothesize that human preterm uterine contractions can be safely and objectively inhibited with a weak electrical current provided by an electrical inhibition (EI)/uterine pacemaker device. This effect can be assessed by the use of a non-invasive tocodynamometer. It has been previously been shown that the frequency of contractions during preterm labor can be lowered by EI applied by the use of an intravaginal catheter carrying electrodes similar to a cardiac pacemaker (Karsdon et al). The investigators hypothesize that this effect relates to the timing and length of EI exposure.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Wong-Baker pain score ≤ 6
- Pregnancy Depression Scale score < 16
- Informed consent form signed and dated by patient
- Be willing and able to comply with study requirements
- Be between 18-50 years of age
- Be between 23 to 36 5/7 weeks pregnant with a singleton gestation
- Cervical dilation of ≤ 6 cm
- A normal spontaneous vaginal delivery (NSVD) expected
Suspected to have preterm labor, as defined by the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics, as follows.78
- Persistent uterine contractions (4 every 20 minutes, or 8 every 60 minutes)
- And any one or more of the following:
- Documented cervical change
1 cm cervical dilatation and progressing
-> 80% cervical effacement
- Be admitted to the maternity unit with the diagnosis of preterm labor or preterm contractions
Exclusion Criteria:
- Severe preeclampsia
- Severe abruption placenta
- Abnormal placentation (i.e. placenta previa)
- Rupture of amniotic membranes
- Active preterm labor with cervical dilation > 6 cm
- Exposed amniotic membranes
- Vaginal bleeding > 10 cc
- Frank chorioamnionitis
- Fetal death
- Fetal anomaly incompatible with life
- Severe fetal growth restriction (EFW < 5%)
- Uterine anomalies (i.e. bicornuate uterus, uterine didelphys)
- Mature fetal lung studies
- Maternal cardiac arrhythmias
- HIV, Hepatitis C, Hepatitis B
- History of herpes simplex virus (HSV)
- A permanent cardiac pacemaker
- A fetal cardiac arrhythmia
- Contraindication for tocolysis e.g. premature rupture of the amniotic membranes allowing for ascending intrauterine infection with group B streptococcus or GBS (beta hemolytic streptococcus, S. agalactiae) or other micro-organisms.
- IV or po narcotic pain medication < 12 hours prior to admission (regional anesthesia, long acting oral maintenance opiates i.e. methadone, Suboxone, Subutex not included in exclusion criteria)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 60 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period.
At the end of the intervention period there will be a 20-minute post-intervention control period.
The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
|
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os.
The electrode connectors are attached to the EI device.
Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing.
Usually 5-10mA of current is sufficient, but 20 mA is a maximum.
Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
|
|
Experimental: 80 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period.
At the end of the intervention period there will be a 20-minute post-intervention control period.
The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
|
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os.
The electrode connectors are attached to the EI device.
Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing.
Usually 5-10mA of current is sufficient, but 20 mA is a maximum.
Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
|
|
Experimental: 120 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period.
At the end of the intervention period there will be a 20-minute post-intervention control period.
The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
|
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os.
The electrode connectors are attached to the EI device.
Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing.
Usually 5-10mA of current is sufficient, but 20 mA is a maximum.
Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uterine contraction frequency during labor as measured by external uterine tocodynamometric monitoring
Time Frame: Change from 20, 40, and 80 minutes
|
Change from 20, 40, and 80 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
FHR pattern as measured by the maternal-fetal monitor
Time Frame: Change from 60 and 120 minutes
|
Change from 60 and 120 minutes
|
|
EMG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
|
Change from 60 and 120 minutes
|
|
EHG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
|
Change from 60 and 120 minutes
|
|
fECG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
|
Change from 60 and 120 minutes
|
|
Maternal pain medication administration
Time Frame: Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
|
Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
|
|
Maternal heart rate
Time Frame: Change from 60 and 120 minutes
|
Change from 60 and 120 minutes
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events
Time Frame: Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
|
Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jeffrey Karsdon, MD, New York University Lagone Medical Center
- Principal Investigator: John Smulian, MD, University of Florida
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201601699 - A
- OCR26522 (Other Identifier: UF OnCore)
- E-BIO CORP (Other Identifier: PRO00038898)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Labor
-
University Hospital, Strasbourg, FranceRecruitingPreterm Delivery | Threatened Preterm LaborFrance
-
Ain Shams UniversityRecruitingPreterm Labor With Preterm DeliveryEgypt
-
PreTeL, IncDuke University; University of RochesterRecruitingPreterm Birth | Threatened Preterm Labor | PreTerm LaborUnited States
-
Shiraz University of Medical SciencesCompletedManaging Preterm Labor
-
Ain Shams Maternity HospitalCompletedThreatened Preterm LaborEgypt
-
Konya Meram State HospitalRecruitingPregnancy Preterm | Preterm Labor Without DeliveryTurkey
-
Hospital Clinico Universitario de SantiagoFundación Ramón DomínguezWithdrawnThreatened Preterm Labor
-
PreTeL, IncUniversity of RochesterCompletedPreterm Labor | Pregnancy Preterm | Labor; IrregularUnited States
-
Istanbul University - Cerrahpasa (IUC)Kilis 7 Aralik UniversityCompletedPreterm Labor | Preterm Labor with Preterm Delivery in Third Trimester | Preterm Spontaneous Labor with Preterm DeliveryTurkey
-
Assiut UniversityUnknown
Clinical Trials on Electrical Uterine Pacemaker
-
Winthrop University HospitalWithdrawn
-
Montefiore Medical CenterCompleted
-
Centre Hospitalier Universitaire, AmiensCompleted
-
CMC Ambroise ParéTerminatedHeart Failure | Cardiac Resynchronization TherapyFrance
-
Ajou University School of MedicineRecruitingObesity | Arrhythmias, Cardiac | Cardiovascular Morbidity | Pacemaker ComplicationKorea, Republic of
-
Region GävleborgUnknown
-
Abbott Medical DevicesTerminated
-
University of PennsylvaniaActive, not recruitingMayer Rokitansky Kuster Hauser Syndrome | Uterine Factor Infertility | Uterine Agenesis | Infertility, Female, of Uterine OriginUnited States
-
Imperial College LondonBritish Heart FoundationRecruitingBradycardia | Left Bundle Branch Area Pacing | His Bundle Pacing | Right Ventricular Pacing | PacingUnited Kingdom, Ireland, Slovenia
-
Nanchong Central HospitalRecruitingLaparoscopic Surgery | Inguinal Hernia | Randomized Controlled TrialChina